Company Search:
Advanced Search
Sponsored Links
Imexpharm Corp Company Snapshot
Imexpharm Corp operates within the Medicinals and botanicals sector. In addition to historical fundamental analyses, the complete report available to purchase compares Imexpharm Corp with three other companies in this sector in Vietnam: Medipharco Pharmaceutical JSC (2018 sales of 987.82 billion Dong [US$42.57 million] ), Mekophar Chemical Pharma JSC (1.16 trillion Dong [US$49.88 million] ), and OPC Pharmaceutical JSC (1.00 trillion Dong [US$43.21 million] ).

Sales Analysis. During the year ended December of 2018, sales at Imexpharm Corp were 1.18 trillion Dong (US$51.07 million). This is a very small increase of 1.7% versus 2017, when the company's sales were 1.17 trillion Dong. This was the fifth consecutive year of sales increases at Imexpharm Corp (and since 2013, sales have increased a total of 41%).
Company ReportsSubscriptions
Looking For More?
Purchace an In-Depth Report
Imexpharm Corp
  Stock Performance Chart for Imexpharm Corp
  Stock Data: Recent Stock Performance:
  Current Price (4/12/2019): 51,200
(Figures in Dong)
1 Week 1.0%   13 Weeks -2.5%  
4 Weeks -3.6%   52 Weeks -6.4%  
Imexpharm Corp Key Data:
  Ticker: IMP Country: Vietnam
  Exchanges: Major Industry: Pharmaceuticals & Biotechnology
    Sub Industry: Medicinals & Botanicals
  2018 Sales 1,184,817,729,231
(Year Ending Jan 2019).
Employees: 605
  Currency: Dong Market Cap: 2,529,349,580,800
  Fiscal Yr Ends: December Shares Outstanding: 49,401,359
  Share Type: Closely Held Shares: 15,061,220
Feedback | Terms and Conditions | Privacy Policy | Site Index
CorporateInformation® website and selected data Copyright © 2000 - by The Winthrop Corporation. All Rights Reserved. Except for quotations by established news media, no pages on this site may be reproduced, stored in a retrieval system, or transmitted for commercial purposes, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior written permission. Information is believed reliable, but accuracy, completeness and opinions are not guaranteed.